Aurinia Pharmaceuticals Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Aurinia Pharmaceuticals Inc. (AUPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.10 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 1.49M shares, a 636.14% increase year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.61M shares, a 26.36% decline year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 41.00K shares, a 77.72% decline year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 112.00K shares, a 35.26% decline year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.54M shares, a 399.80% increase from fiscal 2024.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 509.00K shares, a 33.03% decline from fiscal 2023.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 760.00K shares, a 80.58% decline from fiscal 2022.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 3.91M shares, a 71.85% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 1.49M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 3.10M shares 10-Q · filed 2026-08-06 | 3.14M shares derived: sum of 3 quarters · filed 2026-08-06 | 3.25M shares derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | 1.61M shares 10-Q · filed 2026-05-07 | 1.65M shares derived: sum of 2 quarters · filed 2026-05-07 | 1.76M shares derived: sum of 3 quarters · filed 2026-05-07 | 1.97M shares derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-12-31 | 41.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 153.00K shares derived: sum of 2 quarters · filed 2026-02-26 | 355.00K shares derived: sum of 3 quarters · filed 2026-02-26 | 2.54M shares 10-K · filed 2026-02-26 | |
| 2025-09-30 | 112.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 314.00K shares derived: sum of 2 quarters · filed 2025-11-04 | 2.50M shares 10-Q · filed 2025-11-04 | 2.69M shares derived: sum of 4 quarters · filed 2025-11-04 | |
| 2025-06-30 | 202.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | 2.39M shares 10-Q · filed 2025-07-31 | 2.58M shares derived: sum of 3 quarters · filed 2025-07-31 | 2.75M shares derived: sum of 4 quarters · filed 2025-07-31 | |
| 2025-03-31 | 2.19M shares 10-Q · filed 2025-05-12 | 2.37M shares derived: sum of 2 quarters · filed 2025-05-12 | 2.55M shares derived: sum of 3 quarters · filed 2025-05-12 | 2.63M shares derived: sum of 4 quarters · filed 2025-05-12 | |
| 2024-12-31 | 184.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 357.00K shares derived: sum of 2 quarters · filed 2025-02-27 | 446.00K shares derived: sum of 3 quarters · filed 2025-02-27 | 509.00K shares 10-K · filed 2025-02-27 | |
| 2024-09-30 | 173.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 262.00K shares derived: sum of 2 quarters · filed 2024-11-07 | 325.00K shares 10-Q · filed 2024-11-07 | 410.00K shares derived: sum of 4 quarters · filed 2024-11-07 | |
| 2024-06-30 | 89.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | 152.00K shares 10-Q · filed 2024-08-01 | 237.00K shares derived: sum of 3 quarters · filed 2024-08-01 | 354.00K shares derived: sum of 4 quarters · filed 2024-08-01 | |
| 2024-03-31 | 63.00K shares 10-Q · filed 2024-05-02 | 148.00K shares derived: sum of 2 quarters · filed 2024-05-02 | 265.00K shares derived: sum of 3 quarters · filed 2024-05-02 | 591.00K shares derived: sum of 4 quarters · filed 2024-05-02 | |
| 2023-12-31 | 85.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | 202.00K shares derived: sum of 2 quarters · filed 2024-02-15 | 528.00K shares derived: sum of 3 quarters · filed 2024-02-15 | 760.00K shares 10-K · filed 2024-02-15 | |
| 2023-09-30 | 117.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 443.00K shares derived: sum of 2 quarters · filed 2023-11-02 | 675.00K shares 10-Q · filed 2023-11-02 | 779.00K shares derived: sum of 4 quarters · filed 2023-11-02 | |
| 2023-06-30 | 326.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 558.00K shares 10-Q · filed 2023-08-03 | 662.00K shares derived: sum of 3 quarters · filed 2023-08-03 | 1.41M shares derived: sum of 4 quarters · filed 2023-08-03 | |
| 2023-03-31 | 232.00K shares 10-Q · filed 2023-05-04 | 336.00K shares derived: sum of 2 quarters · filed 2023-05-04 | 1.08M shares derived: sum of 3 quarters · filed 2023-05-04 | 1.34M shares derived: sum of 4 quarters · filed 2023-05-04 | |
| 2022-12-31 | 104.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 852.00K shares derived: sum of 2 quarters · filed 2023-02-28 | 1.11M shares derived: sum of 3 quarters · filed 2023-02-28 | 3.91M shares 10-K · filed 2023-02-28 | |
| 2022-09-30 | 748.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 1.01M shares derived: sum of 2 quarters · filed 2022-11-03 | 3.81M shares 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | 261.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 3.06M shares 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | 2.80M shares 10-Q · filed 2022-05-10 | ||||
| 2021-12-31 | 2.28M shares 10-K · filed 2022-02-28 | ||||
| 2020-12-31 | 7.13M shares 10-K · filed 2022-02-28 | 7.57M shares 10-K · filed 2021-02-24 | |||
| 2019-12-31 | 2.52M shares 10-K · filed 2022-02-28 | ||||
| 2018-12-31 | 3.00M shares 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |